透過您的圖書館登入
IP:18.188.91.44
  • 學位論文

Pcpc07f2抑制LPS活化噬菌細胞發炎反應之機轉探討

The anti-inflammatory mechanisms of pcpc07f2 on lipopolysaccharide-stimulated phagocytes

指導教授 : 黃德富

摘要


發炎反應即個體遭遇到外界有害刺激,像是病原菌、有害化學物質、傷口感染、組織受損時,體內所產生的自然防禦機制。適當的發炎反應得以協助人體抵擋來自外界的傷害,清除病原菌,藉以恢復健康。然而過度甚而失去控制的強烈發炎反應,其產生的發炎相關激素與機制,往往會在體內不斷累積並放大反應,最終於器官組織造成損害,引發一系列的相關疾病。近來許多研究發現,發炎反應的確與關節炎、多發性硬化、氣喘、動脈硬化等慢性疾病有所相關,甚至某些癌症的發生也歸咎於持續而激烈的發炎反應。正因如此,研究開發有效的抗發炎藥物,減輕患者的發炎症狀,並試圖終止強烈的發炎反應,也成了現今許多專家學者與藥廠努力的方向與動力。 在實驗室初步篩藥過程中,發現一化學合成物質pcpc07f2具有抑制巨噬細胞釋放細胞激素的能力,引發我們進一步探究其抗發炎能力與機轉的興趣。首先確認了實驗中所用濃度並不會影響噬菌細胞株的生存率。接著在抑制噬菌細胞受到LPS 活化後釋放發炎性細胞激素之測試中,我們發現pcpc07f2在10μg/ml (約30μM)即能有效抑制由LPS 100ng/ml在原生性小鼠巨噬細胞、細胞株RAW264.7巨噬細胞、亦或細胞株THP-1單核細胞所引發之TNF-α與IL-6釋放,且此抑制作用呈現明顯的濃度相關性。除此之外,對於LPS 100ng/ml活化細胞株RAW264.7巨噬細胞後,其產生之移動現象(migration) 以及大量釋放nitric oxide的發炎反應,pcpc07f2也都能在10μg/ml (30μM)時達抑制作用,同樣此抑制作用呈現明顯的劑量相關性。最後,延伸pcpc07f2之抗發炎能力,將其運用至LPS誘發之敗血症動物模式中,結果發現pcpc07f2 (8μg/g)能有效降低敗血症小鼠血清中的發炎細胞激素含量(TNF-α與IL-6),並明顯降低LPS誘發敗血症小鼠之死亡率。 而對於LPS刺激活化巨噬細胞後所產生的下游訊息傳遞鏈之中,我們檢視了MAPK 路徑中的三種重要激酶:p-38、ERK、JNK的磷酸化現象,以及NF-κB路徑中重要調控因子: IκB的降解情形 (degradation)。研究結果發現,在給予pcpc07f2之後,p-38、ERK、JNK這些MAPK重要激酶的磷酸化都有被抑制的現象,而抑制NF-κB活化的IκB,其降解情形也可被pcpc08f2所回復(reverse),進而抑制NF-κB的活化。此外,我們也使用了MAPK和NF-κB inhibitor來研究兩種訊息傳遞路徑和發炎激素之間的關聯性,發現它們可以抑制LPS刺激活化之巨噬細胞釋放發炎性細胞激素與nitric oxide。 綜合以上所述,我們可以推測pcpc07f2可能經由抑制MAPK路徑中的三種重要激酶p-38、ERK、JNK的磷酸化,以及抑制NF-κB此轉錄因子的活化,來進行其抑制發炎的能力。當然,詳細的作用機轉還有待更多方面的實驗進一步來探討。

並列摘要


Macrophages play a vital role in inflammation and innate immune responses. Foreign pathogens recognized by macrophages trigger a serial of signaling cascades upon ligand-receptor stimulation, then resulting in releasing several pro-inflammatory and anti-inflammatory cytokines, and activating other immune cells. In this study, we used lipopolysaccharide (LPS), a component of the gram-negative bacterial cell wall for activating macrophages, as an experimental model. The pro-inflammatory cytokines, such as TNF-α and IL-6 increased significantly after LPS stimulation as measured by ELISA. We found pcpc07f2, a synthetic benzimidazole compound, concentration-dependently (10~90μM) inhibited LPS (100ng/ml)-induced TNF-α and IL-6 release in macrophages (RAW 264.7 cells), and the inhibition appeared more obvious in primary macrophages. However, pcpc07f2 did not affect the cell viability. Regarding the anti-inflammation effects of pcpc07f2 on LPS-induced septic animal model, we also found that pcpc07f2 significantly reduced pro-inflammatory cytokines release and also reduced LPS-induced mortality in a dose-dependent manner. Furthermore, pcpc07f2 also inhibited macrophage migration and NO production induced by LPS. We further examined if pcpc07f2 affects the activation of nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) pathways in LPS-induced RAW 264.7 cells by Western blotting analysis. Pcpc07f2 concentration-dependently inhibited LPS-induced extracellular signal-regulated kinase 1/2 (ERK1/2), JNK, and p38 phosphorylation, and suppressed LPS-induced NF-κB activation, suggesting that pcpc07f2 decreased TNF-α, IL-6 and NO production via the inactivation of ERK1/2, JNK, and p38 ,and NF-κB signal pathway. Taken together, we suggest that pcpc07f2 may be used as therapeutic approach for the treatment of inflammatory diseases.

並列關鍵字

inflammation cytokine macrophage

參考文獻


Ajizian SJ, English BK, Meals EA. 1999. Specific inhibitors of p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways block inducible nitric oxide synthase and tumor necrosis factor accumulation in murine macrophages stimulated with lipopolysaccharide and interferon-gamma. J Infect Dis 179(4):939-944.
Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29(7):1303-1310.
Bone RC, Grodzin CJ, Balk RA. 1997. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 112(1):235-243.
Borsch-Haubold AG, Pasquet S, Watson SP. 1998. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase. J Biol Chem 273(44):28766-28772.
Bradley JR. 2008. TNF-mediated inflammatory disease. J Pathol 214(2):149-160.

延伸閱讀